Disruptions in these regulatory pathways contribute to the pathogenesis of T1DM and T2DM (4–7) NAFLD, and CKD, often manifesting as hyperglucagonemia and hepatic glucagon resistance. The gene discussed is GCG; the disease is type 2 diabetes mellitus.